
Metabolic Research Peptides · 20mg vial
Retatrutide
Retatrutide (LY3437943) is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents one of the most advanced metabolic research peptides currently being studied, showing significant results in clinical weight management trials.
Research has demonstrated Retatrutide's ability to improve insulin sensitivity, regulate appetite signalling, and support meaningful reductions in body weight. As a triple receptor agonist, it combines the complementary mechanisms of GLP-1 (satiety), GIP (metabolic enhancement), and glucagon (energy expenditure) in a single compound.
Composition & Purity
Retatrutide (LY3437943), Lyophilized powder
For research purposes only
Compound: Retatrutide (LY3437943) — GLP-1/GIP/Glucagon triple agonist
Concentration: 20mg lyophilized powder
Purity: ≥99.9% (HPLC verified)
Storage: Refrigerate at 2–8°C. Protect from light. Reconstitute with bacteriostatic water prior to use.
COA: Available on request.
- Size
- 20mg vial
- Weight
- 20mg
